Skip to main content
SpringerLink
Log in

Cannabinoid and Marijuana Neurobiology

  • Chapter
  • First Online:
Cannabis in Medicine

  • 1495 Accesses

Abstract

The convergence of political, financial, medical, and basic science interests is transforming the field of marijuana science. The past decade has seen a 140-fold increase in the scientific literature compared with 1960, catalyzed by changes in our perception of marijuana and by the discovery of an entirely new signaling system, the endocannabinoid system in living organisms. Shortly after this discovery, revelations appeared on how plant-based cannabinoids (phytocannabinoids) and de novo synthetically produced cannabinoids target and modulate this system in the brain and in other organs. The past decade has also witnessed a steep rise in marijuana use in the United States. The principal target of marijuana is the multifunctional endocannabinoid signaling system, which modulates a vast range of functions – behavioral, cognitive, endocrine, immune, and motor – in the brain and has an equally central role in shaping the function of many organ systems and metabolism in peripheral tissues. With the potency of marijuana and number of users rising, the impact of marijuana on physiology, pathophysiology, cognitive function, and psychiatric conditions is likely to rise. We have embarked on a vast human experiment without informed consent. This chapter provides an overview of the endocannabinoid signaling system, how THC affects the neurobiology of cannabinoids, and implications of this newly found knowledge for public health and public policy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019;269(1):5–15.

    PubMed  Google Scholar 

  2. Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: Terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ(9)-THC at human CB(1) and CB(2) receptors. Cannabis Cannabinoid Res. 2019;4(3):165–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Armenian P, Darracq M, Gevorkyan J, Clark S, Kaye B, Brandehoff NP. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology. 2018;134(Pt A):82–91.

    CAS  PubMed  Google Scholar 

  4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Amer Chem Soc. 1964;86:1646–7.

    CAS  Google Scholar 

  5. Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. Science. 1970;169(3945):611–2.

    CAS  PubMed  Google Scholar 

  6. Mechoulam R, Shvo Y, Hashish I. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073–8.

    CAS  PubMed  Google Scholar 

  7. Howlett AC. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 1984;35(17):1803–10.

    CAS  PubMed  Google Scholar 

  8. Howlett AC, Champion TM, Wilken GH, Mechoulam R. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 1990;29(2):161–5.

    CAS  PubMed  Google Scholar 

  9. Bidaut-Russell M, Devane WA, Howlett AC. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem. 1990;55(1):21–6.

    CAS  PubMed  Google Scholar 

  10. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience. 1994;63(3):637–52.

    CAS  PubMed  Google Scholar 

  11. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–4.

    CAS  PubMed  Google Scholar 

  12. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol. 1992;42(5):838–45.

    CAS  PubMed  Google Scholar 

  13. Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther. 2000;292(3):886–94.

    CAS  PubMed  Google Scholar 

  14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.

    CAS  PubMed  Google Scholar 

  15. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.

    CAS  PubMed  Google Scholar 

  16. Irving A, Abdulrazzaq G, Chan SLF, Penman J, Harvey J, Alexander SPH. Cannabinoid receptor-related orphan G protein-coupled receptors. Adv Pharmacol. 2017;80:223–47.

    CAS  PubMed  Google Scholar 

  17. Hu SS, Mackie K. Distribution of the endocannabinoid System in the central nervous System. Handb Exp Pharmacol. 2015;231:59–93.

    CAS  PubMed  Google Scholar 

  18. Elphick MR. The evolution and comparative neurobiology of endocannabinoid signaling. Philos Trans R Soc Lond Ser B Biol Sci. 2012;367(1607):3201–15.

    CAS  Google Scholar 

  19. John WS, Martin TJ, Nader MA. Behavioral determinants of cannabinoid self-administration in old world monkeys. Neuropsychopharmacology. 2017;42(7):1522–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Justinová Z, Redhi GH, Goldberg SR, Ferré S. Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Δ9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. J Neurosci. 2014;34(19):6480–4.

    PubMed  PubMed Central  Google Scholar 

  21. Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, Goldberg SR, Justinova Z. Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Psychopharmacology. 2016;233(10):1867–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Wakeford AG, Flax SM, Pomfrey RL, Riley AL. Adolescent delta-9-tetrahydrocannabinol (THC) exposure fails to affect THC-induced place and taste conditioning in adult male rats. Pharmacol Biochem Behav. 2016;140:75–81.

    CAS  PubMed  Google Scholar 

  23. Ponzoni L, Moretti M, Braida D, Zoli M, Clementi F, Viani P, Sala M, Gotti C. Increased sensitivity to Δ(9)-THC-induced rewarding effects after seven-week exposure to electronic and tobacco cigarettes in mice. Eur Neuropsychopharmacol. 2019;29(4):566–76.

    CAS  PubMed  Google Scholar 

  24. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci. 2008;1139:434–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Howlett AC, Abood ME. CB(1) and CB(2) receptor pharmacology. Adv Pharmacol. 2017;80:169–206.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol. 2009;88:335–69.

    CAS  PubMed  Google Scholar 

  27. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62:588–631.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Alpár A, Di Marzo V, Harkany T. At the tip of an iceberg: prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biol Psychiatry. 2016;79(7):e33–45.

    PubMed  Google Scholar 

  29. Alpár A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J, Cameron GA, Hanics J, Morris CV, Fuzik J, Kovacs GG, Cravatt BF, Parnavelas JG, Andrews WD, Hurd YL, Keimpema E, Harkany T. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signaling. Nat Commun. 2014;5:4421.

    PubMed  PubMed Central  Google Scholar 

  30. Sanchez-Rodriguez MA, Gomez O, Esteban PF, Garcia-Ovejero D, Molina-Holgado E. The endocannabinoid 2-arachidonoy glycerol regulates oligodendrocyte progenitor cell migration. Biochem Pharmacol. 2018;157:180–8.

    CAS  PubMed  Google Scholar 

  31. https://abcdstudy.org/.

  32. Fine JD, Moreau AL, Karcher NR, Agrawal A, Rogers CE, Barch DM, Bogdan R. Association of prenatal Marijuana exposure with psychosis proneness among children in the adolescent brain cognitive development (ABCD) study. JAMA Psychiat. 2019;76(7):762–4.

    Google Scholar 

  33. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience. 2003;118:681–94.

    CAS  PubMed  Google Scholar 

  34. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry. 2004;56:909–15.

    CAS  PubMed  Google Scholar 

  35. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22:325–36.

    CAS  PubMed  Google Scholar 

  36. Leech SL, Richardson GA, Goldschmidt L, Day NL. Prenatal substance exposure: effects on attention and impulsivity of 6-year olds. Neurotoxicol Teratol. 1999;21:109–18.

    CAS  PubMed  Google Scholar 

  37. Maccarrone M, Guzmán M, Mackie K, Doherty P, Harkany T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci. 2014;15(12):786–801.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Lubman DI, Cheetham A, Yücel M. Marijuana and adolescent brain development. Pharmacol Ther. 2015;148:1–16.

    CAS  PubMed  Google Scholar 

  39. Brumback T, Castro N, Jacobus J, Tapert S. Effects of marijuana use on brain structure and function: neuroimaging findings from a neurodevelopmental perspective. Int Rev Neurobiol. 2016;129:33–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Crowe MS, Nass SR, Gabella KM, Kinsey SG. The endocannabinoid system modulates stress, emotionality, and inflammation. Brain Behav Immun. 2014;42:1–5.

    CAS  PubMed  Google Scholar 

  41. Dow-Edwards D, Silva L. Endocannabinoids in brain plasticity: cortical maturation, HPA axis function and behavior. Brain Res. 2017;1654(Pt B):157–64.

    CAS  PubMed  Google Scholar 

  42. Meyer HC, Lee FS, Gee DG. The role of the endocannabinoid System and genetic variation in adolescent brain development. Neuropsychopharmacology. 2018;43(1):21–33.

    PubMed  Google Scholar 

  43. Lee TT, Gorzalka BB. Evidence for a role of adolescent endocannabinoid signaling in regulating HPA Axis stress responsivity and emotional behavior development. Int Rev Neurobiol. 2015;125:49–84.

    CAS  PubMed  Google Scholar 

  44. Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid System. CNS Drugs. 2018;32(8):697–712.

    CAS  PubMed  Google Scholar 

  45. Madras, BK. World Health Organization, Update of Marijuana and its Medical Use https://www.who.int/medicines/access/controlled-substances/6_2_marijuana_update.pdf.

  46. Harold Kalant, Chapter Thirteen - Effects of Cannabis and Cannabinoids in the Human Nervous System, Editor(s): Bertha Madras, Michael Kuhar, The Effects of Drug Abuse on the Human Nervous System, Academic Press, 2014, Pages 387-422, ISBN 9780124186798, San Diego, CA

    Google Scholar 

  47. lger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci. 2011;34(6):304–15.

    Google Scholar 

  48. de Oliveira RW, Oliveira CL, Guimarães FS, Campos AC. Cannabinoid signaling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders. Acta Neuropsychiatr. 2019;31(1):1–16.

    PubMed  Google Scholar 

  49. Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78:498–509.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Eggan SM, Stoyak SR, Verrico CD, Lewis DA. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology. 2010;35:2060–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Minocci D, et al. Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J Affect Disord. 2011;134:427–30.

    CAS  PubMed  Google Scholar 

  52. Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G, Bogetto F, Maj M. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res. 2010;61(5):400–4.

    CAS  PubMed  Google Scholar 

  53. Steel RW, Miller JH, Sim DA, Day DJ. Delta-9-tetrahydrocannabinol disrupts hippocampal neuroplasticity and neurogenesis in trained, but not untrained adolescent Sprague-Dawley rats. Brain Res. 2014;1548:12–9.

    CAS  PubMed  Google Scholar 

  54. Schiavon AP, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:27–34.

    CAS  Google Scholar 

  55. Prenderville JA, Kelly ÁM, Downer EJ. The role of cannabinoids in adult neurogenesis. Br J Pharmacol. 2015;172(16):3950–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and metaanalysis. Lancet Psychiatry. 2019;12: 995-1010.

    Google Scholar 

  57. Hasan A, von Keller R, Friemel CM, et al. Cannabis use and psychosis: a review of reviews [published online ahead of print, 2019 Sep 28]. Eur Arch Psychiatry Clin Neurosci. 2019; https://doi.org/10.1007/s00406-019-01068-z

  58. Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Lynskey M, Morgan C, Murray RM, EU-GEI WP2 Group. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36.

    PubMed  Google Scholar 

  59. Wright A, Cather C, Gilman J, Evins AE. The changing legal landscape of Cannabis use and its role in youth-onset psychosis. Child Adolesc Psychiatr Clin N Am. 2020;29(1):145–56.

    PubMed  Google Scholar 

  60. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci. 2002;22(22):9771–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, Petrosino S, Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol. 2009;158(2):451–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Patel RS, Patel J, Jaladi PR, Bhimanadham NN, Imran S, Tankersley WE. Burden of Persistent Vomiting With Cannabis Use Disorder: Report From 55,549 Hospitalizations in the United States. Psychosomatics. 2019;60(6):549–555.

    Google Scholar 

  63. Murillo-Rodríguez E. The role of the CB1 receptor in the regulation of sleep. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32(6):1420–7.

    Google Scholar 

  64. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.

    CAS  PubMed  Google Scholar 

  65. Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci. 2011;5:34.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB receptor antagonists. Trends Pharmacol Sci. 2011;32(5):270–80.

    CAS  PubMed  Google Scholar 

  67. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily marijuana smokers. Mol Psychiatry. 2012;17(6):642–9.

    CAS  PubMed  Google Scholar 

  68. Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J. Mattick RP; marijuana cohorts research consortium. Young adult sequelae of adolescent marijuana use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286–93.

    PubMed  Google Scholar 

  69. Shollenbarger SG, Price J, Wieser J, Lisdahl K. Poorer frontolimbic white matter integrity is associated with chronic marijuana use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. Neuroimage Clin. 2015;8:117–25.

    PubMed  PubMed Central  Google Scholar 

  70. CHindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7(4):344–353.

    Google Scholar 

  71. Katona I. Marijuana and endocannabinoid signaling in epilepsy. Handb Exp Pharmacol. 2015;231:285–316.

    CAS  PubMed  Google Scholar 

  72. Samanta D. Cannabidiol: a review of clinical efficacy and safety in epilepsy. Pediatr Neurol. 2019;96:24–9.

    PubMed  Google Scholar 

  73. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12(4):747–768.

    Google Scholar 

  74. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. El Manira A, Kyriakatos A. The role of endocannabinoid signaling in motor control. Physiology (Bethesda). 2010;25(4):230–8.

    Google Scholar 

  76. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009;156(7):1029–40.

    PubMed  PubMed Central  Google Scholar 

  77. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.

    PubMed  Google Scholar 

  78. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci. 2011;5:57.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Morena M, Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol Learn Mem. 2014;112:30–43.

    CAS  PubMed  Google Scholar 

  80. Joshi N, Onaivi ES. Endocannabinoid System components: overview and tissue distribution. Adv Exp Med Biol. 2019;1162:1–12.

    CAS  PubMed  Google Scholar 

  81. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76(7):1341–63.

    CAS  PubMed  Google Scholar 

  83. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J. 2013;280:1918–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Rajesh M, et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol. 2010;160:688–700.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Jouanjus E, et al. Marijuana use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3:e000638.

    PubMed  PubMed Central  Google Scholar 

  86. Steffens S, Pacher P. Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. Br J Pharmacol. 2012;167:313–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Iannotti FA, Silvestri C, Mazzarella E, Martella A, Calvigioni D, Piscitelli F, Ambrosino P, Petrosino S, Czifra G, Bíró T, Harkany T, Taglialatela M, Di Marzo V. The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels. Proc Natl Acad Sci U S A. 2014;111(24):E2472–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html..

  89. Malenczyk K, Keimpema E, Piscitelli F, Calvigioni D, Björklund P, Mackie K, Di Marzo V, Hökfelt TG, Dobrzyn A, Harkany T. Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. Proc Natl Acad Sci U S A. 2015;112(45):E6185–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Smith DR, Stanley CM, Foss T, Boles RG, McKernan K. Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. PLoS One. 2017;12(11):e0187926.

    PubMed  PubMed Central  Google Scholar 

  91. Minichino A, Senior M, Brondino N, et al. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis [published online ahead of print, 2019 Jun 5]. JAMA Psychiatry. 2019;76(9):914–923.

    Google Scholar 

  92. Manza P, Yuan K, Shokri-Kojori E, Tomasi D, Volkow ND. Brain structural changes in cannabis dependence: association with MAGL [published online ahead of print, 2019 Nov 6]. Mol Psychiatry. 2019; https://doi.org/10.1038/s41380-019-0577-z.

  93. Madras BK. Tinkering with THC-to-CBD ratios in marijuana. Neuropsychopharmacology. 2019;44(1):215–6.

    PubMed  Google Scholar 

  94. Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ. Marijuana addiction and the brain: a review. J Neuroimmune Pharmacol. 2018;13(4):438–52.

    PubMed  PubMed Central  Google Scholar 

  95. Manza P, Tomasi D, Volkow ND. Subcortical local functional Hyperconnectivity in marijuana dependence. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(3):285–93.

    PubMed  Google Scholar 

  96. Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA. 2017;317(2):129–30.

    PubMed  Google Scholar 

  97. Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Δ(9)-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Wiers CE, Shokri-Kojori E, Wong CT, Abi-Dargham A, Demiral ŞB, Tomasi D, Wang GJ, Volkow ND. Marijuana abusers show Hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology. 2016;41(10):2596–605.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Ojeil N, Kegeles LS, Xu X, Vadhan NP, Volkow ND, Slifstein M, Abi-Dargham A. Deficits in striatal dopamine release in marijuana dependence. Mol Psychiatry. 2017;22(1):68–75.

    PubMed  Google Scholar 

  100. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R. Effects of marijuana use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.

    Google Scholar 

  101. Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, Tomasi D. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci U S A. 2014;111(30):E3149–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.

    PubMed  Google Scholar 

  103. Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M, Courville A, Hall G, Chen KY, Volkow ND, Kunos G, Huestis MA, Skarulis MC. Metabolic effects of chronic marijuana smoking. Diabetes Care. 2013;36(8):2415–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily marijuana smokers. MolPsychiatry. 2012;17(6):642–9.

    CAS  Google Scholar 

  105. Madras BK. Update of marijuana and its medical uses. 2015. https://www.who.int/medicines/access/controlled-substances/6_2_marijuana_update.pdf.

  106. Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696–712.

    CAS  PubMed  Google Scholar 

  107. Wall MB, Pope R, Freeman TP, Kowalczyk OS, Demetriou L, Mokrysz C, Hindocha C, Lawn W, Bloomfield MA, Freeman AM, Feilding A, Nutt D, Curran HV. Dissociable effects of marijuana with and without cannabidiol on the human brain’s resting-state functional connectivity. J Psychopharmacol. 2019;33(7):822–30.

    CAS  PubMed  Google Scholar 

  108. Roche DJO, Bujarski S, Green R, Hartwell EE, Leventhal AM, Ray LA. Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use. Drug Alcohol Depend. 2019;200:40–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Park JY, Wu LT. Trends and correlates of driving under the influence of alcohol among different types of adult substance users in the United States: a national survey study. BMC Public Health. 2019;19(1):509.

    PubMed  PubMed Central  Google Scholar 

  110. D’Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid changes in CB1 receptor availability in marijuana dependent males after abstinence from marijuana. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(1):60–7.

    PubMed  PubMed Central  Google Scholar 

  111. Lazenka MF, Selley DE, Sim-Selley LJ. Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life Sci. 2013;92(8–9):446–52.

    CAS  PubMed  Google Scholar 

  112. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Marijuana, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293–306.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Harvard Medical School, Boston, MA, USA

    Bertha K. Madras

  2. McLean Hospital, Belmont, MA, USA

    Bertha K. Madras

Authors
  1. Bertha K. Madras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bertha K. Madras .

Editor information

Editors and Affiliations

  1. Springs Rehabilitation PC, Colorado Springs, CO, USA

    Kenneth Finn

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Madras, B.K. (2020). Cannabinoid and Marijuana Neurobiology. In: Finn, K. (eds) Cannabis in Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-45968-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45968-0_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45967-3

  • Online ISBN: 978-3-030-45968-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation